Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer.

摘要: We previously conducted a study of 88 cases prostate cancer in an attempt to identify potential prognostic biomarkers that can distinguish aggressive must be treated immediately. Prostate is serious disease affecting men worldwide and compromises the quality life its patients. Biomarkers studied included chromosome 7 trisomy, 8 HER-2/neu oncogene amplification. These were initially because trisomy amplification gene have been reported many other cancers, including those this laboratory. In view fact was not found play prominent role group specimens we studied, exploration felt warranted. Thus, began pilot c-myc copy number using same protocol for fluorescent situ hybridization direct-labeled SpectrumOrange LSI probe (Vysis, Inc., Downers Grove, IL) on formalin-fixed, paraffin-embedded tissue. From total 36 cancers successfully analyzed, 11 (31%) tumors exhibiting 3 or more positive signals 15% cells. Of these, only (19% studied) had ≥3 20% No case 25% Compared molecular probes tested, faint preparation less optimal than tumor studied. Based information available thus far, conclude increased finding our cohort